Kristine M Ball's Net Worth

$1.71 Million

Estimate Recalculated Nov 8, 2024 09:32PM EST

Who is Kristine M Ball

Kristine M Ball has an estimated net worth of $1.71 Million. This is based on reported shares across multiple companies, which include Relypsa Inc, EXELIXIS INC, Menlo Therapeutics Inc., Atreca, Inc., Forty Seven, Inc., and Oruka Therapeutics, Inc..

SEC CIK

Kristine M Ball's CIK is 0001266163

Past Insider Trading and Trends

2015 was Kristine M Ball's most active year for acquiring shares with 5 total transactions. Kristine M Ball's most active month to acquire stocks was the month of May. 2016 was Kristine M Ball's most active year for disposing of shares, totalling 9 transactions. Kristine M Ball's most active month to dispose stocks was the month of August. 2016 saw Kristine M Ball paying a total of $85,050.00 for 38,250 shares, this is the most they've acquired in one year. In 2016 Kristine M Ball cashed out on 299,515 shares for a total of $1,095,689.88, their largest year based on trade value.

Loading...

Attention insiders:Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!

Relypsa Inc

Chief Financial Officer & SVP
Updated Sep 02, 2016
Form 4
-100.00%
-276.42K
$32.00
-$1.03M
Sep 02, 2016
Disposition
Sep 01
Form 4
-5.00%
-1.48K
$31.89
-$47.20K
Aug 17, 2016
28.11K
Tax
Aug 15
Form 4
34.05%
9.63K
$19.96
-$15.63K
Jun 07, 2016
37.92K
Grant
Jun 03
Form 4
32.88%
7.00K
$12.15
$85.05K
Mar 16, 2016
28.29K
Purchase
Mar 16
Form 4
41.56%
6.25K
Nov 10, 2015
21.29K
Grant
Nov 06
Form 4
-4.12%
-646.00
$22.96
-$14.83K
Sep 03, 2015
15.04K
Sale
ScheduledSep 02
Form 4
-4.51%
-710.00
$24.78
-$17.60K
Aug 19, 2015
15.04K
Sale
Aug 17
Form 4
623.33%
46.75K
Aug 12, 2015
54.25K
Grant
Aug 10
Form 4
-2.63%
-3.52K
$22.32
-$131.26K
Mar 05, 2015
130.37K
Sale
ScheduledMar 03 - Mar 05
Form 4
-2.20%
-3.00K
$19.98
-$96.12K
Jan 23, 2015
133.37K
Sale
ScheduledJan 21
Form 4
42.50K
Aug 18, 2014
42.50K
Grant
Aug 14
Form 3
Nov 14, 2013
Showing 12 results

EXELIXIS INC

Controller & Interim CFO
Updated Dec 12, 2003
Form 4
47.62%
20.00K
Dec 12, 2003
62.00K
Grant
Dec 10
Form 4
-48.75%
-4.67K
$7.01
-$32.78K
Nov 12, 2003
4.91K
Sale
Nov 12
Form 4
-47.57%
-8.70K
$6.92
-$60.20K
Nov 12, 2003
9.59K
Sale
Nov 11
Form 3
Oct 07, 2003
16.50K
Showing 4 results

Menlo Therapeutics Inc.

See Remarks
Updated Dec 16, 2019
Form 4/A
-34.58%
-27.77K
$4.52
-$125.50K
Dec 16, 2019
52.53K
Options
Dec 11
Form 4/A
24.11%
80.30K
Aug 07, 2019
413.42K
Grant
Jul 29
Form 3
Jan 24, 2018
Showing 3 results

Atreca, Inc.

Investor
Updated Jun 15, 2023
Form 4
12.00K
Jun 15, 2023
12.00K
Grant
Jun 13
Form 4
12.00K
Jun 10, 2022
12.00K
Grant
Jun 08
Form 4
12.00K
Jun 11, 2021
12.00K
Grant
Jun 09
Form 4
12.00K
Jun 15, 2020
12.00K
Grant
Jun 10
Form 4
24.00K
May 21, 2020
24.00K
Grant
May 20
Form 3
May 21, 2020
Showing 6 results

Forty Seven, Inc.

Investor
Updated Apr 07, 2020
Form 4
-100.00%
-80.00K
Apr 07, 2020
Disposition
Apr 07
Form 4
10.32K
Jun 14, 2019
10.32K
Grant
Jun 12
Form 3
Jun 27, 2018
Showing 3 results

Oruka Therapeutics, Inc.

Investor
Updated Sep 06, 2024
Form 3
Sep 06, 2024
Showing 1 results